322 related articles for article (PubMed ID: 27988211)
1. Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.
Shiu KY; McLaughlin L; Rebollo-Mesa I; Zhao J; Burton H; Douthwaite H; Wilkinson H; Semik V; Dodd PC; Brookes P; Lechler RI; Hernandez-Fuentes MP; Kemper C; Dorling A
Kidney Int; 2017 Feb; 91(2):477-492. PubMed ID: 27988211
[TBL] [Abstract][Full Text] [Related]
2. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
[TBL] [Abstract][Full Text] [Related]
3. B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection.
Shiu KY; McLaughlin L; Rebollo-Mesa I; Zhao J; Semik V; Cook HT; Roufosse C; Brookes P; Bowers RW; Galliford J; Taube D; Lechler RI; Hernandez-Fuentes MP; Dorling A
Kidney Int; 2015 Sep; 88(3):560-8. PubMed ID: 25830760
[TBL] [Abstract][Full Text] [Related]
4. Monitoring alloimmune response in kidney transplantation.
Bestard O; Cravedi P
J Nephrol; 2017 Apr; 30(2):187-200. PubMed ID: 27245689
[TBL] [Abstract][Full Text] [Related]
5. Expression patterns of B cells in acute kidney transplant rejection.
Carpio VN; Noronha Ide L; Martins HL; Jobim LF; Gil BC; Külzer AS; Loreto Mda S; Gonçalves LF; Manfro RC; Veronese FV
Exp Clin Transplant; 2014 Oct; 12(5):405-14. PubMed ID: 25299368
[TBL] [Abstract][Full Text] [Related]
6. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching.
Rohan VS; Taber DJ; Moussa O; Pilch NA; Denmark S; Meadows HB; McGillicuddy JW; Chavin KD; Baliga PK; Bratton CF
Exp Clin Transplant; 2017 Feb; 15(1):47-55. PubMed ID: 27267614
[TBL] [Abstract][Full Text] [Related]
7. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation.
Bestard O; Cruzado JM; Lucia M; Crespo E; Casis L; Sawitzki B; Vogt K; Cantarell C; Torras J; Melilli E; Mast R; Martinez-Castelao A; Gomà M; Reinke P; Volk HD; Grinyó JM
Kidney Int; 2013 Dec; 84(6):1226-36. PubMed ID: 23783240
[TBL] [Abstract][Full Text] [Related]
8. Rejection of the Renal Allograft in the Absence of Demonstrable Antibody and Complement.
Zhao X; Huang G; Randhawa S; Zeng G; Lunz J; Randhawa P
Transplantation; 2017 Feb; 101(2):395-401. PubMed ID: 26901079
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
10. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
[TBL] [Abstract][Full Text] [Related]
11. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
[TBL] [Abstract][Full Text] [Related]
13. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.
Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA
Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes: Results From Clinical Trials in Organ Transplantation-17.
Faddoul G; Nadkarni GN; Bridges ND; Goebel J; Hricik DE; Formica R; Menon MC; Morrison Y; Murphy B; Newell K; Nickerson P; Poggio ED; Rush D; Heeger PS;
Transplantation; 2018 Apr; 102(4):673-680. PubMed ID: 29189482
[TBL] [Abstract][Full Text] [Related]
16. Pre-transplant donor-specific Interferon-gamma-producing cells and acute rejection of the kidney allograft.
Slavcev A; Rybakova K; Svobodova E; Slatinska J; Honsova E; Skibova J; Viklicky O; Striz I
Transpl Immunol; 2015 Oct; 33(2):63-8. PubMed ID: 26254561
[TBL] [Abstract][Full Text] [Related]
17. Impact of preformed T-cell alloreactivity by means of donor-specific and panel of reactive T cells (PRT) ELISPOT in kidney transplantation.
Gandolfini I; Crespo E; Baweja M; Jarque M; Donadei C; Luque S; Montero N; Allesina A; Perin L; Maggiore U; Cravedi P; Bestard O
PLoS One; 2018; 13(7):e0200696. PubMed ID: 30059561
[TBL] [Abstract][Full Text] [Related]
18. Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation.
Lúcia M; Luque S; Crespo E; Melilli E; Cruzado JM; Martorell J; Jarque M; Gil-Vernet S; Manonelles A; Grinyó JM; Bestard O
Kidney Int; 2015 Oct; 88(4):874-87. PubMed ID: 26176829
[TBL] [Abstract][Full Text] [Related]
19. CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection.
Doberer K; Kläger J; Gualdoni GA; Mayer KA; Eskandary F; Farkash EA; Agis H; Reiter T; Reindl-Schwaighofer R; Wahrmann M; Cohen G; Haslacher H; Bond G; Simonitsch-Klupp I; Halloran PF; Böhmig GA
Transplantation; 2021 Feb; 105(2):451-457. PubMed ID: 32235256
[TBL] [Abstract][Full Text] [Related]
20. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
